Patient-reported outcomes (PROs) in the randomized, phase III IMpower150 study of atezolizumab (atezo) + chemotherapy (chemo) ± bevacizumab (bev) vs chemo + bev in 1L nonsquamous metastatic NSCLC (mNSCLC)

Abstract only

Saved in:

Bibliographic Details
Published in:	Journal of clinical oncology Vol. 36; no. 15_suppl; p. 9047
Main Authors:	Reck, Martin, Karagiannis, Tom, Wehler, Thomas, Shtivelband, Mikhail, Gonzalez-Larriba, Jose-Luis, Rothenstein, Jeffrey, Frueh, Martin, Deng, Yu, Lopez-Chavez, Ariel, Sandler, Alan, Socinski, Mark A.
Format:	Journal Article
Language:	English
Published:	20-05-2018
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!